Literature DB >> 21478242

In vitro trypanocidal activity of DB745B and other novel arylimidamides against Trypanosoma cruzi.

Cristiane França Da Silva1, Angela Junqueira, Marli Maria Lima, Alvaro José Romanha, Policarpo Ademar Sales Junior, Chad E Stephens, Phanneth Som, David W Boykin, Maria de Nazaré Correia Soeiro.   

Abstract

OBJECTIVES: As part of a search for new therapeutic opportunities to treat chagasic patients, in vitro efficacy studies were performed to characterize the activity of five novel arylimidamides (AIAs) against Trypanosoma cruzi.
METHODS: The trypanocidal effect against T. cruzi was evaluated by light microscopy through the determination of IC₅₀ values. Cytotoxicity was determined by MTT assays against mouse cardiomyocytes.
RESULTS: Our data demonstrated the trypanocidal efficacy of these new compounds against bloodstream trypomastigotes and intracellular amastigotes, exhibiting IC₅₀ values ranging from 0.015 to 2.5 and 0.02 to0.2 μM, respectively. One of the compounds, DB745B, was also highly active against a broad panel of isolates, including those naturally resistant to benznidazole. DB745B showed higher in vitro efficacy than the reference drugs used to treat patients (benznidazole IC₅₀= 12.94 μM) and to prevent blood bank infection (gentian violet IC₅₀= 30.6 μM).
CONCLUSIONS: AIAs represent promising new chemical entities against T. cruzi and are also potential trypanocidal agents to prevent transfusion-associated Chagas' disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21478242     DOI: 10.1093/jac/dkr140

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  Evaluation of arylimidamides DB1955 and DB1960 as candidates against visceral leishmaniasis and Chagas' disease: in vivo efficacy, acute toxicity, pharmacokinetics, and toxicology studies.

Authors:  Xiaohua Zhu; Qiang Liu; Sihyung Yang; Toufan Parman; Carol E Green; Jon C Mirsalis; Maria de Nazaré Correia Soeiro; Elen Mello de Souza; Cristiane França da Silva; Denise da Gama Jaen Batista; Chad E Stephens; Moloy Banerjee; Abdelbasset A Farahat; Manoj Munde; W David Wilson; David W Boykin; Michael Zhuo Wang; Karl A Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

Review 2.  Chagas disease and transfusion medicine: a perspective from non-endemic countries.

Authors:  Andrea Angheben; Lucia Boix; Dora Buonfrate; Federico Gobbi; Zeno Bisoffi; Simonetta Pupella; Giorgio Gandini; Giuseppe Aprili
Journal:  Blood Transfus       Date:  2015-10       Impact factor: 3.443

3.  Successful Aspects of the Coadministration of Sterol 14α-Demethylase Inhibitor VFV and Benznidazole in Experimental Mouse Models of Chagas Disease Caused by the Drug-Resistant Strain of Trypanosoma cruzi.

Authors:  Francisca Hildemagna Guedes-da-Silva; Denise da Gama Jaén Batista; Cristiane França Da Silva; Beatriz Philot Pavão; Marcos Meuser Batista; Otacílio Cruz Moreira; Letícia Rocha Quintino Souza; Constança Britto; Girish Rachakonda; Fernando Villalta; Galina I Lepesheva; Maria de Nazaré Correia Soeiro
Journal:  ACS Infect Dis       Date:  2019-01-23       Impact factor: 5.084

4.  Efficacy of Novel Pyrazolone Phosphodiesterase Inhibitors in Experimental Mouse Models of Trypanosoma cruzi.

Authors:  Julianna Siciliano de Araújo; Cristiane França da Silva; Denise da Gama Jaén Batista; Aline Nefertiti; Ludmila Ferreira de Almeida Fiuza; Cristina Rosa Fonseca-Berzal; Patrícia Bernardino da Silva; Marcos Meuser Batista; Maarten Sijm; Titilola D Kalejaiye; Harry P de Koning; Louis Maes; Geert Jan Sterk; Rob Leurs; Maria de Nazaré Correia Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

5.  In Vitro and In Vivo Trypanosomicidal Action of Novel Arylimidamides against Trypanosoma cruzi.

Authors:  F H Guedes-da-Silva; D G J Batista; M B Meuser; K C Demarque; T O Fulco; J S Araújo; P B Da Silva; C F Da Silva; D A Patrick; S M Bakunova; S A Bakunov; R R Tidwell; G M Oliveira; C Britto; O C Moreira; M N C Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

6.  In vitro and in vivo studies of the biological activity of novel arylimidamides against Trypanosoma cruzi.

Authors:  J S De Araújo; C F Da Silva; D G J Batista; P B Da Silva; M B Meuser; C A F Aiub; M F V da Silva; C F Araújo-Lima; M Banerjee; A A Farahat; C E Stephens; A Kumar; D W Boykin; M N C Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2014-03-03       Impact factor: 5.191

7.  Activities of psilostachyin A and cynaropicrin against Trypanosoma cruzi in vitro and in vivo.

Authors:  Cristiane França da Silva; Denise da Gama Jaen Batista; Julianna Siciliano De Araújo; Marcos Meuser Batista; Jessica Lionel; Elen Mello de Souza; Erica Ripoll Hammer; Patricia Bernardino da Silva; Maria De Mieri; Michael Adams; Stefanie Zimmermann; Matthias Hamburger; Reto Brun; Wolfgang Schühly; Maria de Nazaré Correia Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2013-08-12       Impact factor: 5.191

Review 8.  Novel amidines and analogues as promising agents against intracellular parasites: a systematic review.

Authors:  M N C Soeiro; K Werbovetz; D W Boykin; W D Wilson; M Z Wang; A Hemphill
Journal:  Parasitology       Date:  2013-04-08       Impact factor: 3.234

9.  Di-cationic arylimidamides act against Neospora caninum tachyzoites by interference in membrane structure and nucleolar integrity and are active against challenge infection in mice.

Authors:  Michelle Schorer; Karim Debache; Fabienne Barna; Thierry Monney; Joachim Müller; David W Boykin; Chad E Stephens; Andrew Hemphill
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-04-02       Impact factor: 4.077

10.  In vitro and in vivo investigation of the efficacy of arylimidamide DB1831 and its mesylated salt form--DB1965--against Trypanosoma cruzi infection.

Authors:  Cristiane França da Silva; Denise da Gama Jaen Batista; Gabriel Melo Oliveira; Elen Mello de Souza; Erica Ripoll Hammer; Patricia Bernardino da Silva; Anissa Daliry; Julianna Siciliano Araujo; Constança Britto; Ana Carolina Mondaine Rodrigues; Zongying Liu; Abdelbasset A Farahat; Arvind Kumar; David W Boykin; Maria de Nazaré Correia Soeiro
Journal:  PLoS One       Date:  2012-01-23       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.